Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size. (2020)

• Record Type: Journal Article
• Authors: Berthon, Celine; Nudel, Morgane; Boyle, Eileen M.; Goursaud, Laure; Boyer, Thomas; Marceau, Alice; Quesnel, Bruno
• Is Part Of: Leukemia research reports. Volume 13(2020)
• Publication Date: 2020
• Subjects: Myeloma -- AML -- CMML -- Azacytidine -- Lenalidomide -- Daratumumab -- Clonality; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2020.100202
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: Synchronous diagnosis of acute myeloid leukemia (AML) and symptomatic multiple myeloma (MM) is a rare situation that poses serious therapeutic difficulties. We report the case of a 68-year-old male which evolved simultaneously to symptomatic MM and AML. Both diseases first responded to treatment for 40 months after 7+3 induction and maintenance therapy of azacytidine + lenalidomide. MM relapsed first and was treated with azacytidine + daratumumab, which led an additional 15 months of progression-free survival. Little myeloid clonal size reduction over time was seen. This case shows that AML and MM can be effectively treated simultaneously using appropriate combinations.